Ipsen Invests $1.6 Billion to Acquire ImCheck for Promising Mid-Stage Antibody in Leukemia Treatment

Ipsen Invests $1.6 Billion to Acquire ImCheck for Promising Mid-Stage Antibody in Leukemia Treatment

Ipsen Invests $1.6 Billion to Acquire ImCheck for Promising Mid-Stage Antibody in Leukemia Treatment